AMRX - Amneal Pharmaceuticals, Inc.
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Bridgewater,
United States
Type: Equity
AMRX price evolution
AMRX
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $49.62 | $51.62 | $99.11 | $95.61 |
| Short term investments | ||||
| Net receivables | $778.64 | $670.48 | $614.69 | $692.55 |
| Inventory | $575.62 | $570.65 | $581.38 | $576.47 |
| Total current assets | $1485.48 | $1380.04 | $1377.86 | $1456.08 |
| Long term investments | ||||
| Property, plant & equipment | $528.94 | $544.78 | $550.14 | $560.8 |
| Goodwill & intangible assets | $1418.48 | $1457.82 | $1489.05 | $1581.16 |
| Total noncurrent assets | $2024.44 | $2076.35 | $2094.71 | $2231 |
| Total investments | ||||
| Total assets | $3509.92 | $3456.4 | $3472.57 | $3687.08 |
| Current liabilities | ||||
| Accounts payable | $635.34 | $569.91 | $546.44 | $569.29 |
| Deferred revenue | ||||
| Short long term debt | $451.65 | $228.66 | $227.62 | $122.51 |
| Total current liabilities | $1114.35 | $834.39 | $846.6 | $760.6 |
| Long term debt | $2273.49 | $2517.16 | $2522.9 | $2682.18 |
| Total noncurrent liabilities | $2453.06 | $2685.64 | $2605.96 | $2772.24 |
| Total debt | $2725.14 | $2745.83 | $2750.52 | $2804.69 |
| Total liabilities | $3567.41 | $3520.03 | $3452.56 | $3532.84 |
| Shareholders' equity | ||||
| Retained earnings | -$575.83 | -$581.82 | -$490.18 | -$391.53 |
| Other shareholder equity | -$30.44 | -$23.71 | -$32.35 | $3.87 |
| Total shareholder equity | -$57.47 | -$63.72 | $19.78 | $330.86 |
| (in millions $) | 31 Jan 2025 | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.11 | $35.23 | $256.74 | |
| Short term investments | ||||
| Net receivables | $614.69 | $796.91 | $663.76 | |
| Inventory | $581.38 | $530.74 | $489.39 | |
| Total current assets | $1377.86 | $1411.82 | $1520.11 | |
| Long term investments | ||||
| Property, plant & equipment | $550.14 | $589.36 | $639 | |
| Goodwill & intangible assets | $1489.05 | $1694.95 | $1759.94 | |
| Total noncurrent assets | $2094.71 | $2387.52 | $2419.56 | |
| Total investments | ||||
| Total assets | $3472.57 | $3799.34 | $3939.66 | |
| Current liabilities | ||||
| Accounts payable | $546.44 | $165.98 | $592.96 | |
| Deferred revenue | ||||
| Short long term debt | $227.62 | $104.64 | $46.04 | |
| Total current liabilities | $846.6 | $752.8 | $677.24 | |
| Long term debt | $2522.9 | $2692.46 | $2830.02 | |
| Total noncurrent liabilities | $2605.96 | $2862.56 | $2895.45 | |
| Total debt | $2750.52 | $2845.14 | $2876.06 | |
| Total liabilities | $3452.56 | $3500.92 | $3572.69 | |
| Shareholders' equity | ||||
| Retained earnings | -$490.18 | -$406.18 | -$276.2 | |
| Other shareholder equity | -$32.35 | $9.94 | -$24.83 | |
| Total shareholder equity | $19.78 | $298.42 | $360.34 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $701.78 | $659.19 | $616.98 | |
| Cost of revenue | $451.83 | $421.13 | $427.15 | |
| Gross Profit | $249.95 | $238.06 | $189.83 | |
| Operating activities | ||||
| Research & development | $36.05 | $39.3 | $46.09 | |
| Selling, general & administrative | $116.46 | $112.59 | $109 | |
| Total operating expenses | $154.48 | $248.71 | $189.34 | |
| Operating income | $95.47 | -$10.65 | $0.48 | |
| Income from continuing operations | ||||
| EBIT | $75.33 | -$19.78 | -$29.22 | |
| Income tax expense | $3.62 | $6.16 | $9.88 | |
| Interest expense | $65.72 | $65.7 | $59.55 | |
| Net income | ||||
| Net income | $5.99 | -$91.64 | -$98.65 | |
| Income (for common shares) | $5.99 | -$91.64 | -$98.65 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2393.61 | $2212.3 | $2093.67 | $1992.52 |
| Cost of revenue | $1573.04 | $1427.6 | $1324.7 | $1364.13 |
| Gross Profit | $820.57 | $784.71 | $768.97 | $628.39 |
| Operating activities | ||||
| Research & development | $163.95 | $195.69 | $201.85 | $179.93 |
| Selling, general & administrative | $429.68 | $399.7 | $365.5 | $326.73 |
| Total operating expenses | $630.69 | $880.82 | $616.06 | $537.24 |
| Operating income | $189.88 | -$96.11 | $152.92 | $91.16 |
| Income from continuing operations | ||||
| EBIT | $135.09 | $35.05 | $158.15 | $132.7 |
| Income tax expense | $8.45 | $6.66 | $11.2 | -$104.36 |
| Interest expense | $210.63 | $158.38 | $136.32 | $146 |
| Net income | ||||
| Net income | -$83.99 | -$129.99 | $10.62 | $91.06 |
| Income (for common shares) | -$83.99 | -$129.99 | $10.62 | $91.06 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | $5.99 | -$91.64 | -$98.65 | $9.68 |
| Operating activities | ||||
| Depreciation | $55.57 | $55.53 | $56.93 | $57.21 |
| Business acquisitions & disposals | $4.99 | |||
| Stock-based compensation | $6.72 | $6.72 | $5.97 | $6.69 |
| Total cash flows from operations | $39.66 | -$4.41 | $135.82 | $81.39 |
| Investing activities | ||||
| Capital expenditures | -$10.7 | -$10.06 | -$11.79 | -$12.48 |
| Investments | ||||
| Total cash flows from investing | -$6.46 | -$19.76 | -$31.69 | -$13.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.36 | $0.03 | $0.04 | $0.41 |
| Net borrowings | -$27 | -$15.38 | $64.16 | -$53.94 |
| Total cash flows from financing | -$35.09 | -$23.16 | -$100.83 | -$86.58 |
| Effect of exchange rate | -$0.1 | -$0.17 | $0.2 | -$0.3 |
| Change in cash and equivalents | -$2 | -$47.49 | $3.5 | -$18.98 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$83.99 | -$129.99 | $10.62 | $91.06 |
| Operating activities | ||||
| Depreciation | $229.4 | $240.18 | $233.41 | $235.39 |
| Business acquisitions & disposals | -$84.71 | -$146.54 | -$251.36 | |
| Stock-based compensation | $26.82 | $31.85 | $28.41 | $20.75 |
| Total cash flows from operations | $345.58 | $65.1 | $241.82 | $379 |
| Investing activities | ||||
| Capital expenditures | -$46.8 | -$48.8 | -$50.94 | -$61.84 |
| Investments | ||||
| Total cash flows from investing | -$69.19 | -$174.31 | -$194.18 | -$317.55 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.45 | $0.66 | $0.85 | $0.32 |
| Net borrowings | $22.65 | -$38.27 | -$79.18 | $138.89 |
| Total cash flows from financing | -$212.57 | -$106.62 | -$138.12 | $131.81 |
| Effect of exchange rate | $0.07 | -$5.68 | $0.1 | $1.04 |
| Change in cash and equivalents | $63.88 | -$221.51 | -$90.38 | $194.3 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.33 |
| Quick ratio | 0.82 |